A case of pembrolizumab-induced hypopituitarism subsequent to hypothyroidism
-
- Fujii Keitaro
- Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Tsukuba
-
- Imai Takayuki
- Department of Head and Neck Surgery, Miyagi Cancer Center
-
- Miyakura Yuya
- Department of Head and Neck Surgery, Miyagi Cancer Center
-
- Hasegawa Kohsei
- Department of Head and Neck Surgery, Miyagi Cancer Center
-
- Nakazato Akira
- Department of Head and Neck Surgery, Miyagi Cancer Center
-
- Morita Shinkichi
- Department of Head and Neck Surgery, Miyagi Cancer Center
-
- Saijyo Satoshi
- Department of Head and Neck Surgery, Miyagi Cancer Center
-
- Asada Yukinori
- Department of Head and Neck Surgery, Miyagi Cancer Center
Bibliographic Information
- Other Title
-
- ペムブロリズマブ投与後の甲状腺機能低下症に続いて下垂体機能低下症を合併した1例
Search this article
Abstract
A 60-year-old man was treated with pembrolizumab for recurrence of lung metastasis after surgery for hypopharyngeal carcinoma. Three months after the first dose, severe hypothyroidism was observed. This was thought to be an immune-related adverse event （irAE） and treatment was temporarily discontinued. Levothyroxine was started, thyroid function recovered, and pembrolizumab was restarted. Seven months after the first dose, general malaise and anorexia were observed. On the basis of the decrease in serum ACTH and cortisol levels, we diagnosed hypopituitarism as an irAE. Hydrocortisone was administered and the general condition promptly improved. Hypothyroidism induced by immune checkpoint inhibitors is a frequently observed irAE and may be secondary to hypopituitarism, as in this case.
Journal
-
- Toukeibu Gan
-
Toukeibu Gan 48 (3), 295-300, 2022
Japan Society for Head and Neck Cancer
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390293887769070080
-
- ISSN
- 18818382
- 13495747
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
-
- Abstract License Flag
- Disallowed